MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

20th International Congress » Parkinson's Disease: Clinical Trials II and Non-PD Clinical Trials

Date: Thursday, June 23, 2016

Time: 12:00pm-1:30pm

Session Type: Guided Poster Tour

Meeting: 20th International Congress

12:00pm-1:30pm
A healthy volunteer phase 1 study of RE-024, a potential phosphopantothenate replacement therapy for patients with pantothenate kinase-associated neurodegeneration (PKAN)

R.D. Marshall, A. Harring-Abbott, K. Lucey, K. Leach, M. Beconi, J. Hunt, H. Plotkin (San Diego, CA, USA)

12:00pm-1:30pm
Acute admissions in people with Parkinson’s – More than just frailty

N. Leopold, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

12:00pm-1:30pm
Copper chelation efficacy of alginate/chitosan based D-penicillamine nanoparticles in rat model of non-Wilsonian brain copper toxicosis

A. Pal, B.R. Thapa, R.K. Vasishta, R. Prasad (Chandigarh, India)

12:00pm-1:30pm
Development of a human neuroblastoma model of pantothenate kinase-associated neurodegeneration

A. Di Marco, G. Auciello, A. Vecchi, D. Vignone, M.R. Battista, E. Bracacel, F. Bonelli, E. Nizi, E. Monteagudo, M. Beconi (Pomezia, Italy)

12:00pm-1:30pm
Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study

P.A. LeWitt, M.I. Freed, M. Leinonen, A. Sedkov, H. Murck (West Bloomfield, MI, USA)

12:00pm-1:30pm
KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia

S.A. Factor, R.A. Hauser, S. Siegert, G.S. Liang, C.F. O'Brien (Atlanta, GA, USA)

12:00pm-1:30pm
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress

S. Muhlack, M. Kinkel, L. Herrmann, L. Tönges, T. Müller (Bochum, Germany)

12:00pm-1:30pm
Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III

B.L. Greco, T. Simuni, J. Lowell, K.C. Hodgeman, S. Sharma, C.A. Marshall, J. Denmark, W. Galpern, J.L. Goudreau, C. Meuiner, C. Sia, C.A. Thomas, D. Young, K.M. Biglan (Rochester, NY, USA)

12:00pm-1:30pm
Patient experiences following Parkinson’s disease treatment with inhaled levodopa: Results from a Phase 2b study

P. LeWitt, A. Niyazov, A. Sedkov, H. Murck, A. Guo (West Bloomfield, MI, USA)

12:00pm-1:30pm
Transcranial versus root repeated magnetic stimulation as a treatment of psychogenic movement disorders

B. Garcin, C. Hubsch, L. Lliescu, L. Naccache, M. Vidailhet, E. Fournier, F. Mesrati, E. Roze, B. Degos (Paris, France)

« View all sessions from the 20th International Congress.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley